Cystic Fibrosis Therapeutics Market Size, Share & Trends Report

Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration, By Region, And Segment Forecasts, 2018 - 2025

  • Published Date: Jun 2017
  • Report ID: GVR-1-68038-865-7
  • Number of Pages: 80
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016

Table of Contents

Chapter 1. Methodology and Scope
                 1.1. Research Methodology
                 1.2. Research Scope & Assumptions
                 1.3. List of Data Sources
Chapter 2. Executive Summary
                 2.1. Market Snapshot
Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends & Scope
                 3.1. Market Segmentation
                 3.2. Market Dynamics
                     3.2.1. Market driver analysis
                     3.2.2. Market restraint analysis
                 3.3. Key Opportunities Prioritized
                 3.4. Industry Analysis - Porter's
                 3.5. Cystic Fibrosis Therapeutics Market-SWOT Analysis, By Factor (Political & Legal, Economic and Technological), 2015
Chapter 4. Cystic Fibrosis Therapeutics Market: Drug Class Estimates & Trend Analysis
                 4.1. Cystic Fibrosis Therapeutics Market Share by Drug Class, 2016 & 2025 (USD Million)
                 4.2. Pancreatic Enzyme Supplements
                     4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 4.3. Mucolytics
                     4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 4.4. Bronchodilators
                     4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 4.5. CFTR Modulators
                     4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 5. Cystic Fibrosis Therapeutics Market: Route of Administration Estimates & Trend Analysis
                 5.1. Cystic Fibrosis Therapeutics Market Share by Route of Administration, 2016 & 2025 (USD Million)
                 5.2. Oral Drugs
                     5.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 5.3. Inhaled Drugs
                     5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 6. Cystic Fibrosis Therapeutics Market: Regional Outlook, by Drug Class and Route of Administration
                 6.1. Cystic Fibrosis Therapeutics Market Shares by Region, 2016 & 2025 (USD Million)
                 6.2. North America
                     6.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.2.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.2.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.2.4. The U.S.
                         6.2.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.2.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.2.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.2.5. Canada
                         6.2.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.2.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.2.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.3. Europe
                     6.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.3.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.3.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.3.4. Germany
                         6.3.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.3.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.3.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.3.5. UK
                         6.3.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.3.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.3.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.4. Asia Pacific
                     6.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.4.4. China
                         6.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.4.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.4.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.4.5. Japan
                         6.4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.4.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.4.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.5. Latin America
                     6.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.5.4. Brazil
                         6.5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.5.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.5.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.5.5. Mexico
                         6.5.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.5.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.5.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.6. Middle East & Africa
                     6.6.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.6.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.6.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.6.4. South Africa
                         6.6.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.6.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.6.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
Chapter 7. Competitive Landscape
                 7.1. Strategic Framework
                 7.2. Company Profiles
                     7.2.1. AbbVie Inc.
                         7.2.1.1. Company overview
                         7.2.1.2. Financial performance
                         7.2.1.3. Product benchmarking
                         7.2.1.4. Strategic initiatives
                     7.2.2. F. Hoffmann-La Roche Ltd
                         7.2.2.1. Company overview
                         7.2.2.2. Financial performance
                         7.2.2.3. Product benchmarking
                         7.2.2.4. Strategic initiatives
                     7.2.3. Gilead
                         7.2.3.1. Company overview
                         7.2.3.2. Financial performance
                         7.2.3.3. Product benchmarking
                         7.2.3.4. Strategic initiatives
                     7.2.4. Novartis AG
                         7.2.4.1. Company overview
                         7.2.4.2. Financial performance
                         7.2.4.3. Product benchmarking
                         7.2.4.4. Strategic initiatives
                     7.2.5. Vertex Pharmaceuticals Incorporated
                         7.2.5.1. Company overview
                         7.2.5.2. Financial performance
                         7.2.5.3. Product benchmarking
                         7.2.5.4. Strategic initiatives
                     7.2.6. AIT (Advanced Inhalation Therapies)
                         7.2.6.1. Company overview
                         7.2.6.2. Financial performance
                         7.2.6.3. Product benchmarking
                         7.2.6.4. Strategic initiatives
                     7.2.7. Alaxia
                         7.2.7.1. Company overview
                         7.2.7.2. Financial performance
                         7.2.7.3. Product benchmarking
                         7.2.7.4. Strategic initiatives
                     7.2.8. Teva Pharmaceutical Industries Ltd.
                         7.2.8.1. Company overview
                         7.2.8.2. Financial performance
                         7.2.8.3. Product benchmarking
                         7.2.8.4. Strategic initiatives
                     7.2.9. Merck & Co. Inc.
                         7.2.9.1. Company overview
                         7.2.9.2. Financial performance
                         7.2.9.3. Product benchmarking
                         7.2.9.4. Strategic initiatives
                     7.2.10. Alcresta Therapeutics, Inc.
                         7.2.10.1. Company overview
                         7.2.10.2. Financial performance
                         7.2.10.3. Product benchmarking
                         7.2.10.4. Strategic initiatives
                     7.2.11. ALLERGAN
                         7.2.11.1. Company overview
                         7.2.11.2. Financial performance
                         7.2.11.3. Product benchmarking
                         7.2.11.4. Strategic initiatives
                     7.2.12. AstraZeneca
                         7.2.12.1. Company overview
                         7.2.12.2. Financial performance
                         7.2.12.3. Product benchmarking
                         7.2.12.4. Strategic initiatives


List of Tables

TABLE 1 North America cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 2 North America cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 3 U.S. cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 4 U.S. cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 5 Canada cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 6 Canada cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 7 Europe cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 8 Europe cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 9 Germany cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 10 Germany cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 11 UK cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 12 UK cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 15 China cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 16 China cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 17 Japan cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 18 Japan cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 19 Latin America cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 20 Latin America cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 21 Mexico cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 22 Mexico cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 23 Brazil cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 24 Brazil cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 25 Middle East and Africa cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 26 Middle East and Africa cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 27 South Africa cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 28 South Africa cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key Opportunity Priorities
FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Cystic fibrosis therapeutics market, Heat Map Analysis
FIG. 13 Cystic fibrosis therapeutics market drug class outlook key takeaways
FIG. 14 Cystic fibrosis therapeutics market: drug class movement analysis
FIG. 15 Pancreatic enzyme supplements market estimates and forecast, 2014 - 2025 (USD Million)
FIG. 16 Mucolytics market estimates and forecast, 2014 - 2025 (USD Million)
FIG. 17 Bronchodilators market estimates and forecast, 2014 - 2025 (USD Million)
FIG. 18 CFTR modulators market estimates and forecast, 2014 - 2025 (USD Million)
FIG. 19 Cystic fibrosis therapeutics market route of administration outlook key takeaways
FIG. 20 Cystic fibrosis therapeutics market: route of administration movement analysis
FIG. 21 Oral drugs market estimates and forecast, 2014 - 2025 (USD Million)
FIG. 22 Inhaled drugs market estimates and forecast, 2014 - 2025 (USD Million)
FIG. 23 Cystic fibrosis therapeutics market Regional outlook, 2016 & 2025
FIG. 24 North America cystic fibrosis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 U.S. cystic fibrosis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 Canada cystic fibrosis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 27 Europe cystic fibrosis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 28 Germany cystic fibrosis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 29 UK cystic fibrosis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 30 Asia Pacific cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 China cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 Japan cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 Latin America cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 34 Brazil cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 35 Mexico cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 36 MEA cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 37 South Africa cystic fibrosis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 38 Competitive strategy adopted by leading players

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.